Department of the Army October 2, 2009 – Federal Register Recent Federal Regulation Documents
Results 1 - 4 of 4
Department of Defense Historical Advisory Committee; Meeting
In accordance with Section 10(a) (2) of the Federal Advisory Committee Act (Pub. L. 92-463), announcement is made of the following committee meeting:
Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Application Concerning Novel Use and Method of Rapamycin To Treat Toxic Shock
Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/231,348 entitled ``Novel Use and Method of Rapamycin to Treat Toxic Shock,'' filed August 5, 2009. The United States Government, as represented by the Secretary of the Army, has rights to this invention.
Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Application Concerning Monoclonal Antibodies Against Glycoprotein of Ebola Sudan Boniface Virus
Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/239,266 entitled ``Monoclonal Antibodies Against Glycoprotein of Ebola Sudan Boniface Virus,'' filed September 2, 2009. The United States Government, as represented by the Secretary of the Army, has rights to this invention.
Notice of Availability of a Novel Fiberglass Technology for Exclusive, Partially Exclusive or Non-Exclusive Licenses
The Department of the Army announces the general availability of exclusive, partially exclusive or non-exclusive licenses relative to a novel fiberglass technology (e-glass; s-glass, etc.) as described in U.S. Patent Application 11/639,221 filed on 12/15/06; entitled ``Nano- Textured Solid Surfaces and Methods for Producing Same''; Jensen and McKnight. Any license shall comply with 35 U.S.C. 209 and 37 CFR part 404.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
